- 专利标题: HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS
-
申请号: US15758038申请日: 2016-09-08
-
公开(公告)号: US20180251444A1公开(公告)日: 2018-09-06
- 发明人: Michael OHLMEYER , Nilesh ZAWARE
- 申请人: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- 申请人地址: US NY New York
- 专利权人: Icahn School of Medicine at Mount Sinai
- 当前专利权人: Icahn School of Medicine at Mount Sinai
- 当前专利权人地址: US NY New York
- 国际申请: PCT/US2016/050685 WO 20160908
- 主分类号: C07D401/04
- IPC分类号: C07D401/04 ; C07D405/04 ; C07D417/04 ; C07D401/14 ; C07D417/14 ; A61P35/00
摘要:
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a therapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
公开/授权文献
信息查询